Chr. Hansen is to acquire Jennewein Biotechnologie for €310m in a deal designed to merge the bioscience firm’s probiotic interests with the gains Jennewein have made in the Human Milk Oligosaccharides (HMO) market.
Research involving Jennewein Biotechnologie suggests breast-fed infants are less likely than bottle-fed infants to contract norovirus infections, adding weight to the protective effects of Human Milk Oligosaccharides (HMOs).
Jennewein Biotechnologie has filed a patent infringement suit against Nestlé concerning the unauthorised use of a human milk oligosaccharide (HMO) purification method for infant formula.